Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Anne J. Gonzales-Luna"'
Publikováno v:
Pharmacoepidemiology, Vol 2, Iss 4, Pp 283-288 (2023)
Vancomycin is not appreciably passaged via the colonic membrane to the gastrointestinal (GI) tract in persons with an intact gut epithelium due to its large chemical structure. However; hospitalized patients with diarrhea often have a disrupted GI tr
Externí odkaz:
https://doaj.org/article/f9d0e09ed91e46a4a356fd4a64ca5a75
Autor:
Abiola O. Olaitan, Chetna Dureja, Madison A. Youngblom, Madeline A. Topf, Wan-Jou Shen, Anne J. Gonzales-Luna, Aditi Deshpande, Kirk E. Hevener, Jane Freeman, Mark H. Wilcox, Kelli L. Palmer, Kevin W. Garey, Caitlin S. Pepperell, Julian G. Hurdle
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decrea
Externí odkaz:
https://doaj.org/article/424d815f462b4e1c9fe133cfb7dbf801
Autor:
Jonathan D. Baghdadi, Mia Wessel, Erik R. Dubberke, Alison Lydecker, Kimberly C. Claeys, Carolyn Alonso, K.C. Coffey, Michael Durkin, Anne J. Gonzales-Luna, Alice Y. Guh, Jennie H. Kwon, Elise Martin, Preeti Mehrotra, Christopher R. Polage, Michael S. Pulia, Clare Rock, Andrew M. Skinner, Valerie M. Vaughn, Tara Vijayan, Michael E. Yarrington, Daniel J. Morgan, for the CDC Prevention Epicenters Program
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 4 (2024)
Abstract Background: Clostridioides difficile infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact of signs, symptoms, a
Externí odkaz:
https://doaj.org/article/546f64248cc848398d91942e1934cbff
Publikováno v:
Gut Microbes, Vol 15, Iss 1 (2023)
ABSTRACTHuman gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysb
Externí odkaz:
https://doaj.org/article/a59465a6c63441e599d89c48b0075931
Autor:
Richard L. Hengel, Claudia P. Schroeder, Jinhee Jo, Timothy E. Ritter, Ramesh V. Nathan, Anne J. Gonzales-Luna, Engels N. Obi, Ryan J. Dillon, Lucinda J. Van Anglen, Kevin W. Garey
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract Background Clostridioides difficile infection (CDI) is associated with high recurrence rates impacting health-related quality of life (HrQOL). However, patient-reported data are lacking particularly in the outpatient setting. We assessed cha
Externí odkaz:
https://doaj.org/article/07dc502960f347a0b814aa9c7e96e398
Publikováno v:
Antibiotics, Vol 12, Iss 9, p 1441 (2023)
Antibiotic use is becoming increasingly challenging with the emergence of multidrug-resistant organisms. Pharmacokinetic (PK) alterations result from complex pathophysiologic changes in some patient populations, particularly those with critical illne
Externí odkaz:
https://doaj.org/article/71dff36db8664539b5fda3dced4f8b4d
Autor:
Anne J. Gonzales-Luna, Travis J. Carlson, Kierra M. Dotson, Kelley Poblete, Gabriela Costa, Julie Miranda, Chris Lancaster, Seth T. Walk, Shawn Tupy, Khurshida Begum, M. Jahangir Alam, Kevin W. Garey
Publikováno v:
Emerging Microbes and Infections, Vol 9, Iss 1, Pp 341-347 (2020)
ABSTRACTClostridioides difficile infection (CDI) is the most prevalent healthcare-associated infection in the United States and carries a significant healthcare system burden. As part of an ongoing, active surveillance system of C. difficile througho
Externí odkaz:
https://doaj.org/article/fb17572c576b443da77f041e41c28561
Autor:
Shanlin Ke, Nira R. Pollock, Xu-Wen Wang, Xinhua Chen, Kaitlyn Daugherty, Qianyun Lin, Hua Xu, Kevin W. Garey, Anne J. Gonzales-Luna, Ciarán P. Kelly, Yang-Yu Liu
Publikováno v:
Gut Microbes, Vol 13, Iss 1 (2021)
Clostridioides difficile (C. difficile) infection is the most common cause of healthcare–associated infection and an important cause of morbidity and mortality among hospitalized patients. A comprehensive understanding of C. difficile infection (CD
Externí odkaz:
https://doaj.org/article/c548e3c030ea4ab39d03e6ce5a69c26d
Publikováno v:
Antibiotics, Vol 11, Iss 2, p 258 (2022)
Antimicrobial resistance to treatments for Clostridioides difficile infection (CDI) poses a significant threat to global health. C. difficile is widely thought to be susceptible to oral vancomycin, which is increasingly the mainstay of CDI treatment.
Externí odkaz:
https://doaj.org/article/638c575b060a42808da420be563e2008
Publikováno v:
Drugs. 83:105-116